Daniel Lynch - Net Worth and Insider Trading
Daniel Lynch Net Worth
The estimated net worth of Daniel Lynch is at least $26 Million dollars as of 2026-07-28. Daniel Lynch is the Director of Blueprint Medicines Corp and owns about 174,342 shares of Blueprint Medicines Corp (BPMC) stock worth over $23 Million. Daniel Lynch is the Director of SpringWorks Therapeutics Inc and owns about 82,944 shares of SpringWorks Therapeutics Inc (SWTX) stock worth over $4 Million. Daniel Lynch is also the Director of bluebird bio Inc and owns about 140 shares of bluebird bio Inc (BLUE) stock worth over $696. Details can be seen in Daniel Lynch's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Daniel Lynch has not made any transactions after 2025-02-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Daniel Lynch
Daniel Lynch Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Daniel Lynch owns 11 companies in total, including Blueprint Medicines Corp (BPMC) , bluebird bio Inc (BLUE) , and Translate Bio Inc (TBIO) among others .
Click here to see the complete history of Daniel Lynch’s form 4 insider trades.
Insider Ownership Summary of Daniel Lynch
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| BPMC | Blueprint Medicines Corp | 2018-02-14 | director |
| BLUE | bluebird bio Inc | 2017-08-31 | director |
| TBIO | Translate Bio Inc | 2020-06-16 | director |
 | | 2018-04-18 | director |
| | 2025-02-20 | director & 10 percent owner |
| | 2014-02-05 | director |
| | 2016-08-26 | director & other: Chairman |
| | 2021-01-06 | director |
| | 2021-10-21 | director & 10 percent owner |
| | 2022-06-08 | director |
| | 2014-02-05 | director |
Daniel Lynch Latest Holdings Summary
Daniel Lynch currently owns a total of 3 stocks. Among these stocks, Daniel Lynch owns 174,342 shares of Blueprint Medicines Corp (BPMC) as of February 14, 2018, with a value of $23 Million and a weighting of 85.27%. Daniel Lynch owns 82,944 shares of SpringWorks Therapeutics Inc (SWTX) as of February 20, 2025, with a value of $4 Million and a weighting of 14.73%. Daniel Lynch also owns 140 shares of bluebird bio Inc (BLUE) as of August 31, 2017, with a value of $696 and a weighting of 0%.
Latest Holdings of Daniel Lynch
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BPMC | Blueprint Medicines Corp | 2018-02-14 | 174,342 | 129.46 | 22,570,315 |
| SWTX | SpringWorks Therapeutics Inc | 2025-02-20 | 82,944 | 46.99 | 3,897,539 |
| BLUE | bluebird bio Inc | 2017-08-31 | 140 | 4.97 | 696 |
Holding Weightings of Daniel Lynch
Daniel Lynch Form 4 Trading Tracker
According to the SEC Form 4 filings, Daniel Lynch has made a total of 0 transactions in Blueprint Medicines Corp (BPMC) over the past 5 years. The most-recent trade in Blueprint Medicines Corp is the sale of 12,500 shares on February 14, 2018, which brought Daniel Lynch around $1 Million.
According to the SEC Form 4 filings, Daniel Lynch has made a total of 3 transactions in SpringWorks Therapeutics Inc (SWTX) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in SpringWorks Therapeutics Inc is the sale of 47,600 shares on February 20, 2025, which brought Daniel Lynch around $3 Million.
According to the SEC Form 4 filings, Daniel Lynch has made a total of 0 transactions in bluebird bio Inc (BLUE) over the past 5 years. The most-recent trade in bluebird bio Inc is the sale of 25 shares on August 31, 2017, which brought Daniel Lynch around $60,000.
Insider Trading History of Daniel Lynch
* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.
- 1
Daniel Lynch Trading Performance
Daniel Lynch Ownership Network
Ownership Network List of Daniel Lynch
Ownership Network Relation of Daniel Lynch
Daniel Lynch Owned Company Details
What does Blueprint Medicines Corp do?
Who are the key executives at Blueprint Medicines Corp?
Daniel Lynch is the director of Blueprint Medicines Corp. Other key executives at Blueprint Medicines Corp include Chief Scientific Officer Percy H. Carter , Chief Commercial Officer Christina Rossi , and director & CEO & President Jeffrey W. Albers .
Blueprint Medicines Corp (BPMC) Insider Trades Summary
Over the past 18 months, Daniel Lynch made no insider transaction in Blueprint Medicines Corp (BPMC). Other recent insider transactions involving Blueprint Medicines Corp (BPMC) include a net sale of 16,763 shares made by Christina Rossi , a net sale of 18,266 shares made by Jeffrey W. Albers , and a net sale of 7,240 shares made by Percy H. Carter .
In summary, during the past 3 months, insiders sold 0 shares of Blueprint Medicines Corp (BPMC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 101,016 shares of Blueprint Medicines Corp (BPMC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 101,016 shares.
Blueprint Medicines Corp (BPMC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Blueprint Medicines Corp Insider Transactions
Daniel Lynch Mailing Address
Above is the net worth, insider trading, and ownership report for Daniel Lynch. Currently GuruFocus does not have mailing address information for Daniel Lynch.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
